Dr. Catherine Diefenbach on the Promise of New Therapies for Mantle Cell Lymphoma

Dr. Catherine Diefenbach on the Promise of New Therapies for Mantle Cell Lymphoma Dr. Catherine Diefenbach on the Promise of New Therapies for Mantle Cell Lymphoma

Education

Podcast About Our Clinical Trials

News About Our Clinical Trials

ACCRU Transformative Research

Dr. Catherine Diefenbach on the Promise of New Therapies for Mantle Cell Lymphoma

ACCRU Transformative Research Podcast:

Episode #2

In this episode, podcast host Dr. Ciara O’Sullivan interviews Dr. Catherine Diefenbach about her innovative research for relapsed mantle cell lymphoma. Dr. Diefenbach is currently director of hematology translational research as well as director of the Clinical Lymphoma Program at NYU’s Langone Perlmutter Cancer Center. Dr. Diefenbach discusses a current ACCRU study that has the potential to prolong the survival of R/R MCL patients, including BTK inhibitor-resistant patients, or even have a role in the frontline treatment of elderly or unfit patients who are ineligible for aggressive chemo-immunotherapy.

For more ACCRU podcast sessions, visit ACCRU Transformative Research @ Podbean »

Go to Top